Educated Patient® Lung Cancer Summit

Watch Elisabeth King, Dr. Edward S. Kim and Terri Conneran answer questions about targeted therapy during the CURE Educated Patient Lung Cancer Summit.

Watch Dr. Edward S. Kim, from City of Hope, discuss targeted therapy during the CURE Educated Patient Lung Cancer Summit.

Watch Elisabeth King, from City of Hope, discuss biomarker testing during the CURE Educated Patient Lung Cancer Summit.

Watch Dr. Farhad Mazdisnian, Dr. Terence Williams and Dr. Antoinette J. Wozniak answer questions about the basics of the disease during the CURE Educated Patient Lung Cancer Summit.

Watch Dr. Terrance M. Williams, from City of Hope, discuss radiation advances during the CURE Educated Patient Lung Cancer Summit.

Watch Dr. Farhard Mazdisnian, from City of Hope, discuss diagnosing early, locally advanced and metastatic disease, during the CURE Educated Patient Lung Cancer Summit.

Although immunotherapy has provided patients with small cell lung cancer with a “light at the end of the tunnel,” an expert from City of Hope argues more research is needed.

Increased use of radiation in lung cancer treatment may be a result of discoveries in research and improved spreading of information on this technology.

More focus is needed on increasing lung cancer screening for patients, especially in those who are eligible for it according to their smoking history.

New advancements in the staging process for lung cancer are leading to faster recoveries and better diagnoses.

Clinical trials are an invaluable resource to the cancer community, as they continually advance treatment options for patients. An expert explains how they work and what patients should know.

Treating lung cancer is more precise than ever, thanks to biomarker testing, which gives clinicians a better understanding of individual’s tumors.

View the full CURE Educated Patient Lung Cancer Summit on demand.

View the full CURE Educated Patient Lung Cancer Summit on demand.

View the full CURE Educated Patient Lung Cancer Summit on demand.

Take a look back at CURE®’s Educated Patient® Lung Cancer Summit with this roundup of stories that highlight what was discussed at this half-day virtual event.

In the field of lung cancer, a number of current studies evaluating the efficacy of adoptive cellular therapies may one day offer patients with non-small cell lung cancer a “high risk, high reward” treatment option, according to Dr. Ben Creelan of the Moffitt Cancer Center.

As the population ages, the incidence of older adults being diagnosed with lung cancer is increasing, though data on how to specifically treat this population are lacking.

An expert discusses ways that small cell lung cancer is diagnosed, how to treat it and how to pivot if the disease spreads or recurs. He also focuses on efforts in the clinical trial space to potentially treat patients more effectively.

View the full CURE Educated Patient Lung Cancer Summit on demand.

Biomarkers play an important role in treatment decisions of many tumors, but in lung cancer they are a deciding factor between which immunotherapy is the best option.

In an interview with CURE®, Dr. Wade T. Iams discussed small cell lung cancer, a subtype of lung cancer that starts from neuroendocrine cells in the lung, how different stages are treated and the potential benefits of having a treatment team to communicate with every step of the way.

Dr. Sally J. York goes over the types of immunotherapy-related side effects, and what patients with lung cancer and their caregivers should look out for.

View all three sessions of the CURE Educated Patient Lung Cancer Summit here!